Perth, Australia – 6 November 2025: NeuroScientific Biopharmaceuticals Limited (ASX: NSB), an innovative Australian biotechnology company developing novel technologies targeted at immune-mediated inflammatory diseases, is pleased to announce the appointment of its Clinical & Scientific Advisory Board with immediate effect.
The Advisory Board will provide strategic guidance across scientific innovation, product development, clinical indications, and patient treatment as the Company advances its proprietary StemSmart™ technology and clinical pipeline. The Board will be led by NSB’s Chief Medical Officer, Dr Catherine Cole, and include Chief Scientific Officer Dr Marian Sturm, alongside a panel of leading clinicians and researchers.
Members of the Advisory Board
• Dr Ashley Irish, MBBS FRACP: Clinical Professor at the University of Western Australia and Lead Renal Transplant Clinician at Fiona Stanley Hospital. Dr Irish has extensive experience in dialysis and renal transplantation, cardiovascular disease, glomerulonephritis, and renal disorders, and serves as Clinical Lead for the WA Country Health Service Renal Program.
• Dr Lena Thin, MClinRes MBBS: Consultant Gastroenterologist at Fiona Stanley Hospital with a focus on Inflammatory Bowel Disease (IBD). Dr Thin is Principal Investigator for the hospital’s IBD research unit, sits on multiple advisory boards, and serves as an executive member of the Australian and New Zealand IBD Research Consortium.
• Dr Michael Musk, MBBS FRACP: Respiratory Physician and Medical Director at Fiona Stanley Hospital. Dr Musk leads the Advanced Lung Disease Unit and has served as Chair of the Lung Transplant Advisory Committee of the Thoracic Society of Australia and New Zealand. He has been Principal Investigator on numerous clinical trials for idiopathic pulmonary fibrosis, transplantation, and bronchiectasis.
• Professor Yuben Moodley, MBBS FRACP MD PhD: Consultant Respiratory Physician at Fiona Stanley Hospital and Professor of Respiratory Medicine at the University of Western Australia. Prof Moodley is Co-Deputy Director at the Institute for Respiratory Health, a Chief Investigator in the Centre for Research Excellence in Pulmonary Fibrosis, and a member of several global advisory boards. His expertise includes pulmonary fibrosis, COPD, and cell biology of the lung.
Dr Catherine Cole, Chief Medical Officer, said:
“I am delighted to be working closely with these distinguished members to further develop NSB’s clinical and scientific strategy for StemSmart™. The combined knowledge and expertise they bring to the table, along with their care for patients with unmet medical needs, will provide a roadmap for future innovation and development at NSB.”
Chief Executive Officer Nathan Smith commented:
“With the appointment of our Advisory Board, NSB now has a strong panel of key opinion leaders across clinical and scientific fields. Their insights will play a pivotal role in supporting our goal of treating patients with unmet medical needs in immune-mediated inflammatory disorders.”
About us:
About NeuroScientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.
Targeting Crohn’s Disease with StemSmart™ Technology
Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn’s disease—a severe and treatment-resistant form of the condition. Favourable outcomes will support the Company’s progression to a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn’s disease. This initiative aligns with NSB’s broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn’s disease, for whom current therapies remain inadequate.
About EmtinB™
EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury. Preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.
Contact details:
Jane Morgan – Investor & Media Relations
+61 (0)405 555 618
[email protected]
